Business
Kelyniam Global Announces 3rd Quarter Results
Kelyniam Global Announces 3rd Quarter Results.
About this update from Kelyniam Global, Inc.
[{"type":"text","content":"\n\n\n\nKelyniam Global Announces 3rd Quarter Results\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nKelyniam Global Announces 3rd Quarter Results\nPR Newswire\nCANTON, Conn., Nov. 15, 2022\n\n\n\nStrong Results to Date and New Partner Announced\nCANTON, Conn., Nov. 15, 2022 /PRNewswire/ -- Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its quarter ended September 30, 2022. \n\"Revenues in Q3 were significantly ahead of last year and we expect continued strong sales performance through the end of the year,\" said Ross Bjella, Kelyniam's Chairman and CEO. \"The quarter over quarter results were particularly exciting because we had an elevated 3rd quarter in 2021 due to pent up Covid related demand. Profitability was impacted due to continued investments in infrastructure necessary to support growth and for additional regulatory consulting. Further, the CustomizedBone® hydroxyapatite implant licensed from Finceramica earlier this year is starting to generate interest from surgeons, particularly for pediatric use in children as young as seven years old.\"\nFinancial highlights for the three months ended September 30, 2022 and the same period in 2021 includes:\nTotal revenue for the year to date of $2,194,435 compared to $1,953,812, an increase of 12.3%, from comparable periods last yearGross margin of $1,738,733 compared to $1,494,067, an increase of 16.4%, from comparable periods last yearOperating Income of $93,523 compared to $140,568\"I am also excited to announce that Kelyniam has been chosen by Singular Health (ASX:SHG) to be their Registered Agent in the U.S., following the recent 510(k) clearance of their new 3DiCom MD software,\" said Bjella. \"This incredible software uniquely allows surgeons to collaboratively visualize CT/MRI and PET scans in 2D and 3D in real-time. We believe this software will revolutionize how surgeons interact with patients and each other when doing surgical planning and that this relationship with Singular Health will help Kelyniam access key inter...